Last reviewed · How we verify
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
The system assesses the heterogeneity of HCC patients in terms of therapeutic outcomes (such as rwPFS, ORR, PRO) and adverse reactions during the process of interventional therapy combined with systemic treatment. It explores the clinical characteristics and biomarker levels of patients related to heterogeneity and builds a machine learning model to predict the risk of adverse reactions, providing evidence support for the construction of a patient-centered individualized decision-making system.
Details
| Lead sponsor | Xuhua Duan |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 2000 |
| Start date | Wed Oct 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sun Oct 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
- Interventional therapy
- Systemic therapy
Countries
China